ADC Therapeutics SA

Good morning and welcome to the ADC Therapeutics first quarter results 2021 financial call. My name is Cheryl and I will be your operator for today's call. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session. During the question and answer session, if you have a question, please press star then one on your touch tone phone. I will now turn the call over to Amanda Hamilton. You may begin.

Thank you, operator. This morning we issued a press release announcing our first quarter 2021 financial results and business updates. This release is available on the ADCT website at ir.adctherapeutics.com under the press releases section. On today's call, Chris Martin, Chief Executive Officer, Jennifer Herron, our Chief Commercial Officer, Jay Feingold, Chief Medical Officer, and Jen Creel, Chief Financial Officer, We'll discuss recent business highlights and review our first quarter 2021 financial results before opening the call for questions. As a reminder, this conference call may contain forward-looking statements. Such statements are subject to risks and uncertainty. For additional information concerning forward-looking statements and factors that could cause actual results to differ materially from those expressed or implied in these statements, we refer you to the section titled Cautionary Statements Regarding Forward-Looking Statements in Exhibit 99.3 of our report on Form 6-K filed with the U.S. Securities and Exchange Commission earlier today. Such statements speak only as of the date of this conference call, and we expressly disclaim any obligation or undertaking to update these forward-looking statements unless required to do so by applicable law. Today's presentation also includes non-IFRS financial measures. These non-IFRS measures have limitations as financial measures and should be considered in addition to and not in isolation or as a substitute for the information prepared in accordance with IFRS. You should refer to the information contained in the company's first quarter earnings release for definitional information and reconciliation of historical non-IFRS measures to the comparable IFRS financial measures. It is now my pleasure to pass the call over to our CEO, Chris Martin. Chris?

Thanks, Amanda, and thank you all for joining us today. The first few months of this year have been transformational and exciting. As you know, we were extremely pleased to receive accelerated FDA approval for Zynlanta on Friday, April the 23rd, a month before the PDUFA date. Based on the broad patient population studied in the Phase II clinical trial, the label includes patients with diffuse large B-cell lymphoma not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma, with the latter being an important point of differentiation. We launched immediately after receiving accelerated approval, making a seamless transition to a fully integrated commercial organization. We were pleased to learn yesterday, less than two weeks since FDA approval, that Ziblanta was added to the NCCN treatment guidelines with a level 2a recommendation. The NCCN treatment guidelines are reflective of the broad indication in the FDA approval. to include not only DLBCL-NOS, but also DLBCL arising from low-grade lymphoma, such as follicular and marginal zone lymphoma, and also high-grade B-cell lymphoma. This rapid addition supports the Zynlanta differentiated profile and highlights the high unmet medical need in this patient population. Continuing to advance our research programs remains a priority for the company, Beyond the first indication for Zyndlanta, we are exploring different combinations and earlier lines of therapy in DLBCL and follicular lymphoma. We're also advancing clinical studies in Hodgkin lymphoma and solid tumors for our second program, CAMI, as well as our earlier stage pipeline. Jay will discuss the pipeline in more detail shortly, but first I would like to turn the call over to Jennifer, our Chief Commercial Officer, to provide some highlights on the first few days of the Zyndlanta launch. Jennifer.